solute carrier family 6 member 20Genealiases: IMINO · SIT1 · XT3 · Xtrp3
Q-omics provides the consensus-scored SLC6A20 profile across patient tissues and cancer cell-line models. SLC6A20 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SLC6A20 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, SLC6A20 RNA expression shows 13,692 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRP, COAD, and ESCA as cancer lineages where SLC6A20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC6A20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC6A20 survival associations across molecular data types. SLC6A20 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC6A20 RNA expression–survival associations across cancer types. High SLC6A20 expression shows unfavorable associations in SCLC, DLBC and KIRC, but favorable associations in KIRP, LUAD and THYM. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SLC6A20 RNA expression.
This table summarizes SLC6A20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC6A20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC6A20 shows lower tumor expression in KIRC, LUSC and KICH and higher tumor expression in COAD, THCA and UCEC. The COAD box plot shows higher SLC6A20 RNA expression in tumor versus normal tissue (log2 FC = +2.281, t-test p < 0.001).
This table shows molecular features associated with SLC6A20 in patient tissues and cancer cell lines. In patient samples, SLC6A20 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC6A20 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and OESOPHAGUS.
